53 related articles for article (PubMed ID: 8632420)
21. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
23. The crystal structure of human endothelin-1 and how it relates to receptor binding.
Wallace BA; Janes RW
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S250-3. PubMed ID: 8587379
[TBL] [Abstract][Full Text] [Related]
24. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
von Geldern TW; Tasker AS; Sorensen BK; Winn M; Szczepankiewicz BG; Dixon DB; Chiou WJ; Wang L; Wessale JL; Adler A; Marsh KC; Nguyen B; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3668-78. PubMed ID: 10479298
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.
Liu G; Kozmina NS; Winn M; von Geldern TW; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1999 Sep; 42(18):3679-89. PubMed ID: 10479299
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Zhang H; Ryono DE; Devasthale P; Wang W; O'Malley K; Farrelly D; Gu L; Harrity T; Cap M; Chu C; Locke K; Zhang L; Lippy J; Kunselman L; Morgan N; Flynn N; Moore L; Hosagrahara V; Zhang L; Kadiyala P; Xu C; Doweyko AM; Bell A; Chang C; Muckelbauer J; Zahler R; Hariharan N; Cheng PT
Bioorg Med Chem Lett; 2009 Mar; 19(5):1451-6. PubMed ID: 19201606
[TBL] [Abstract][Full Text] [Related]
27. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
30. Endothelin-1 induces mucosal mast cell degranulation and tissue injury via ETA receptors.
Boros M; Szalay L; Kaszaki J
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():31S-34S. PubMed ID: 12193049
[TBL] [Abstract][Full Text] [Related]
31. 1,3-Disubstituted-2-carboxy quinolones: highly potent and selective endothelin A receptor antagonists.
Haesslein JL; Baholet I; Fortin M; Iltis A; Khider J; Periers AM; Pierre C; Vevert JP
Bioorg Med Chem Lett; 2000 Jul; 10(13):1487-90. PubMed ID: 10888339
[TBL] [Abstract][Full Text] [Related]
32. In vivo activity of an azole series of CCR2 antagonists.
Smethurst CA; Bevan N; Brooks C; Emmons A; Gough PJ; Mookherjee C; Moores K; Peace S; Philp J; Piercy V; Watson SP; Zippoli M
Bioorg Med Chem Lett; 2012 Dec; 22(23):7252-5. PubMed ID: 23079519
[TBL] [Abstract][Full Text] [Related]
33. [Quantitative relationships of structure and antimicrobial activity in azole-containing chemotherapeutics].
Prodanchuk NG; Snichenko VG; Petrunik IO; Kozyunchenko AP; Patratiĭ VK
Antibiot Khimioter; 1991 May; 36(5):12-4. PubMed ID: 1953162
[TBL] [Abstract][Full Text] [Related]
34. Blocking of the endothelin system: the development of receptor antagonists.
Battistini B; Dussault P
Pulm Pharmacol Ther; 1998; 11(2-3):97-112. PubMed ID: 9918742
[No Abstract] [Full Text] [Related]
35. Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold.
Kotoku M; Maeba T; Fujioka S; Yokota M; Seki N; Ito K; Suwa Y; Ikenogami T; Hirata K; Hase Y; Katsuda Y; Miyagawa N; Arita K; Asahina K; Noguchi M; Nomura A; Doi S; Adachi T; Crowe P; Tao H; Thacher S; Hashimoto H; Suzuki T; Shiozaki M
J Med Chem; 2019 Mar; 62(5):2837-2842. PubMed ID: 30776227
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances in the Synthesis of 1,3-Azoles.
Downer-Riley NK; Jackson YA
Curr Top Med Chem; 2016; 16(30):3617-3626. PubMed ID: 27086792
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors.
Singh A; Kast J; Dirain ML; Huang H; Haskell-Luevano C
ACS Chem Neurosci; 2016 Feb; 7(2):196-205. PubMed ID: 26645732
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds.
Davis MR; Singh EK; Wahyudi H; Alexander LD; Kunicki JB; Nazarova LA; Fairweather KA; Giltrap AM; Jolliffe KA; McAlpine SR
Tetrahedron; 2012 Jan; 68(4):1029-1051. PubMed ID: 22287031
[TBL] [Abstract][Full Text] [Related]
39. Azole endothelin antagonists. 2. Structure-activity studies.
von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
[TBL] [Abstract][Full Text] [Related]
40. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.
von Geldern TW; Hutchins C; Kester JA; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):957-67. PubMed ID: 8632419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
